ContraFect Provides Program Update

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today provided an update on its clinical development timeline for CF-301. The company now expects to initiate the Phase 2 study of CF-301 in patients with Staphylococcus aureus (Staph aureus) bacteremia in mid-2017, as an investigational drug product lot did not meet manufacturing release specifications.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »